Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 4Gynecologic 2Myeloid 1Lymphoid 1CNS 1Breast 1

Conditions

Neuroblastoma 1

Interventions

Temozolomide 299Radiotherapy 219Bevacizumab 139Carboplatin 91Cyclophosphamide 88Etoposide 82Filgrastim 72Vincristine 69Irinotecan 69Magnetic Resonance Spectroscopy 65Cisplatin 59Radiation 58Radiosurgery 52Surgical Procedures, Operative 41Peripheral Blood Stem Cell Transplantation 40Topotecan 39Doxorubicin 39Lomustine 37Carmustine 36sargramostim 35Granulocyte Colony-Stimulating Factor 35Melphalan 34Nivolumab 32Chemotherapy, Adjuvant 32Radiotherapy, Intensity-Modulated 29Isotretinoin 29Everolimus 29Erlotinib Hydrochloride 27Thiotepa 25Vorinostat 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × IL32 protein, human × CNS × Clear all
NCT01576692 2018-11-15

Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma

St. Jude Children's Research Hospital

Phase 1 Completed
34 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡